Rare Tumor Modeling: GIST and Osteosarcoma
Established the first validated PDO models for GIST and osteosarcoma, enabling mutation-specific drug testing in rare mesenchymal tumors.
Challenge
Rare mesenchymal tumors like GIST and osteosarcoma have extremely limited preclinical model options. Patients are often excluded from drug development programs due to lack of representative models.
Approach
PDO models were established from GIST and osteosarcoma patient tissue. Models were validated by IHC and NGS to confirm preservation of key tumor markers (Vimentin, Ki67, SOX9, TP53 for osteosarcoma). Multiple morphological subtypes were captured.
Results:
Successfully established the first validated PDO models for both GIST and osteosarcoma. Mutation-specific drug testing demonstrated differential response based on KIT/PDGFRA mutation status in GIST.
Implication
Expands the reach of precision oncology to rare tumor types, enabling biomarker-driven stratification and drug testing in underserved patient populations.